Platelet-rich Plasma: A Tour d'horizon for its Application in Rheumatoid Arthritis.

Rheumatoid Arthritis (RA) is one of the most common inflammatory diseases, affecting millions of people worldwide, out of which 40% show poor clinical response while 5- 20% do not respond to current medications, including biologic and targeted therapies. Platelet- Rich Plasma (PRP), an autologous blood-derived product enriched with growth factors, has emerged as a new orthobiologic for the treatment of such non-responsive patients. The growth factors present in PRP influence various fundamental processes, including inflammation, angiogenesis, cell migration, and metabolism in RA.